How long retatrutide lasts once mixed is a question with no validated answer under UK regulatory standards. Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes. It holds no marketing authorisation from the MHRA or EMA, meaning no approved reconstitution or stability guidelines exist for use in the UK. Stability timeframes circulating online — including commonly cited figures such as 28 days — are unverified and should not be treated as clinical guidance. Legitimate access remains restricted to approved clinical trials only.

How Long Retatrutide Remains Stable After Reconstitution

No MHRA-approved or manufacturer-validated stability data exist for retatrutide; widely cited timeframes such as 28 days are unverified and should not be treated as clinical guidance.

Retatrutide is an investigational peptide that acts as a triple agonist at GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes (Jastreboff et al., NEJM 2023). It has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and is therefore not legally available as a licensed medicine in the UK. Because no approved UK product licence exists, there are no manufacturer-validated or MHRA-approved reconstitution or stability guidelines for retatrutide.

This means that any figures circulating online about how long retatrutide lasts once mixed — including commonly cited timeframes such as 28 days — are not derived from approved prescribing information and have not been validated by any UK regulatory authority. They should not be treated as clinical guidance.

The only legitimate route to access retatrutide in the UK is through participation in an approved clinical trial. If you are enrolled in such a trial, all reconstitution, storage, and stability questions must be directed to your trial site team or the trial pharmacy. Do not attempt to purchase, reconstitute, or administer retatrutide obtained from any other source, including online peptide suppliers. The MHRA has confirmed that retatrutide does not hold a UK marketing authorisation, and the risks of using unlicensed injectable compounds obtained outside approved trials are serious and cannot be fully mitigated by careful preparation alone.

Correct Storage Conditions for Reconstituted Retatrutide

Retatrutide should only be reconstituted and stored by trained personnel within an approved clinical trial; all storage instructions must come from the trial pharmacy.

Because retatrutide is an investigational medicinal product (IMP) without a UK marketing authorisation, it should only be reconstituted and stored by trained personnel within an approved clinical trial setting, in accordance with the trial protocol and trial pharmacy instructions. Patients should not be reconstituting or storing this product themselves.

If you are a trial participant, your trial site will provide specific written instructions for any at-home storage that forms part of the protocol. Follow those instructions precisely and contact your trial team if you have any questions.

For general context, the following principles apply to the storage of reconstituted injectable peptides in clinical settings:

• Reconstituted solutions are typically stored under refrigeration at 2–8°C and protected from direct light

• Freeze-thaw cycles after reconstitution can disrupt peptide structure and should be avoided

• Vials should be kept sealed and handled using aseptic technique to prevent microbial contamination

• Each vial should be clearly labelled with the date and time of reconstitution

These principles are provided for contextual understanding only. No UK-validated stability data exist for retatrutide specifically, and no storage timeframe can be confirmed without approved manufacturer data. Any storage guidance for retatrutide used within a clinical trial will be provided by the trial pharmacy and must take precedence.

Signs That a Reconstituted Solution Has Degraded

Visual signs of degradation include cloudiness, discolouration, and particulate matter, but chemical degradation can occur without any visible change, making visual inspection alone unreliable.

This section is intended for contextual awareness only. If you are a trial participant and have any concern about the integrity of a prepared dose, contact your trial site team immediately. Do not attempt to assess, use, or 'rescue' a questionable vial yourself.

Physical signs that a reconstituted injectable solution may have degraded include:

• Visible particulate matter — cloudiness, floating particles, or sediment that does not clear upon gentle swirling

• Discolouration — any yellowing, browning, or change from the expected clear, colourless appearance

• Change in consistency — a gel-like or unusually viscous texture may suggest protein aggregation

• Any unusual odour upon opening, which may indicate contamination

Importantly, chemical degradation — including oxidation, deamidation, or hydrolysis of peptide bonds — can occur without any visible change to the solution (EMA/ICH Q5C guideline on stability of biotechnological products). A solution that appears normal may have significantly reduced potency or may contain degradation products with unknown safety profiles. Visual inspection alone cannot confirm that a solution is safe or effective.

If there is any doubt about the integrity of a prepared solution, it must be discarded. Only validated stability data and laboratory analysis can confirm the integrity of a reconstituted peptide. For any concerns arising within a clinical trial, the trial team and trial pharmacy are the appropriate points of contact.

Safe Handling and Disposal of Reconstituted Injectable Peptides

Used needles and syringes must be placed immediately into an approved yellow-lidded sharps bin and returned to an NHS collection point; vials must never be shared between individuals.

Retatrutide is an investigational medicinal product and should only be handled by trained personnel within an approved clinical trial. The following guidance is provided for general awareness and applies to the clinical trial context.

Key safe handling principles for reconstituted injectable peptides include:

• Thorough handwashing before handling vials, syringes, or needles

• Preparation on a clean, flat surface, away from food or drink

• Use of a sterile syringe and needle for each dose; both must be discarded after a single use

• Vials must never be shared between individuals

• Aseptic technique must be maintained throughout preparation and administration

Disposal of sharps must comply with UK regulations. Used needles and syringes should be placed immediately into an approved sharps bin (yellow lid), available from most community pharmacies or GP surgeries. Once full, sharps bins should be returned to a designated NHS collection point and must never be placed in household recycling or general waste (NHS guidance on sharps disposal; Environmental Protection Act 1990 and associated waste regulations).

Unused or expired reconstituted solutions should be returned to a pharmacy or disposed of as clinical waste; they should not be poured down the sink, as peptide compounds may have environmental implications. Your GP surgery or community pharmacy can advise on appropriate local disposal routes (gov.uk clinical waste guidance).

What to Do If You Have Concerns About a Prepared Dose

Do not administer a dose if you have any doubt about its integrity; trial participants should contact their trial team, and anyone experiencing severe symptoms should call 999 or attend A&E immediately.

If you have any uncertainty about the safety, potency, or integrity of a reconstituted dose — whether relating to its appearance, the time elapsed since mixing, storage conditions, or the preparation process — do not administer it. Seek guidance first.

If you are a clinical trial participant, contact your trial site team or trial pharmacist directly. They are the appropriate and authorised point of contact for all questions about your investigational product. If you have obtained retatrutide from any other source, do not use it; seek advice from your GP or call NHS 111.

If you experience any unexpected symptoms after administration — including nausea, vomiting, injection site swelling or redness, signs of allergic reaction (rash, difficulty breathing, swelling of the face or throat), or systemic symptoms such as fever — you should:

• Contact your GP promptly for non-urgent concerns

• Call NHS 111 if you are unsure whether your symptoms require urgent attention

• Call 999 or attend A&E immediately if you experience a severe allergic reaction, chest pain, difficulty breathing, or loss of consciousness

Suspected side effects or adverse reactions to any medicine, including investigational products, should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. This applies to both patients and healthcare professionals and helps the MHRA monitor the safety of medicines used in the UK.

Being open with your healthcare team about any compounds you are using — including unlicensed or investigational products — is essential for your safety and for accurate clinical assessment. Healthcare professionals, including GPs and pharmacists, can provide non-judgemental advice and support.

Current Regulatory Status of Retatrutide in the UK

Retatrutide holds no MHRA or EMA marketing authorisation and is not legally available as a licensed medicine in the UK; access is only possible through approved clinical trials.

Retatrutide is an investigational drug developed by Eli Lilly and Company. It has not received marketing authorisation from the MHRA or the EMA, as confirmed by the MHRA Medicines Database, and is therefore not legally available as a licensed medicine in the UK. It is currently in clinical development; a phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated significant weight reduction in adults with obesity, and further trials are ongoing (see ClinicalTrials.gov for current study identifiers). The development phase may have progressed since the time of writing; readers should check current sources for the latest status.

The MHRA has issued repeated safety warnings about the risks of purchasing unlicensed injectable weight-loss compounds — including GLP-1 receptor agonists and related peptides — from unregulated online sources. These warnings apply equally to retatrutide. Products sold outside licensed channels may be counterfeit, contaminated, incorrectly dosed, or stored inappropriately, all of which pose serious risks to patient safety.

NICE has not issued guidance on retatrutide, as it cannot appraise medicines that do not hold a UK marketing authorisation. Should retatrutide receive MHRA approval in the future, it would be subject to the standard NICE technology appraisal process before being recommended for NHS use.

Legitimate access to retatrutide in the UK is currently only possible through participation in an approved clinical trial. The primary patient-facing resource for finding approved UK trials is the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk). Trials may also be identified via the ISRCTN registry and ClinicalTrials.gov. Sourcing retatrutide through any other route — including online suppliers or unlicensed channels — is not sanctioned, carries significant legal and health risks, and should be avoided. Always consult a registered healthcare professional before considering any unlicensed treatment.

Frequently Asked Questions